Phase 3 Clinical Trials With Primary Completion Dates in December 2021

This is a list of Phase 3 trials with primary completion dates in December 2021 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
ALLK Allakos Inc. 2021-12-01 Phase 3 NCT04322604 A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)
ATNM Actinium Pharmaceuticals, Inc. 2021-12-01 Phase 3 NCT02665065 Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia
BCDA BioCardia, Inc. 2021-12-01 Phase 3 NCT02438306 CardiAMP™ Cell Therapy Heart Failure Trial
ENDP Endo International plc 2021-12-01 Phase 3 NCT03526549 Long-Term Study of EN3835 in Edematous Fibrosclerotic Panniculopathy (Cellulite)
GRTX Galera Therapeutics, Inc. 2021-12-01 Phase 3 NCT03689712 ROMAN: A Study to Investigate the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer
KSPHF Kissei Pharmaceutical Co., Ltd. 2021-12-01 Phase 3 NCT04132050 A Clinical Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788
LNTH Lantheus Holdings, Inc. 2021-12-01 Phase 3 NCT02764801 Contrast-enhanced Ultrasound Evaluation of Chemoembolization
MCRB Seres Therapeutics, Inc. 2021-12-01 Phase 3 NCT03183141 ECOSPOR IV: Open-Label Study, Including Study SERES-012 Extension, Evaluating SER-109 in Recurrent Clostridioides Difficile Infection
MDGL Madrigal Pharmaceuticals, Inc. 2021-12-01 Phase 3 NCT04197479 A Phase 3 Study to Evaluate the Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease (NAFLD) Patients
MDGL Madrigal Pharmaceuticals, Inc. 2021-12-01 Phase 3 NCT03900429 A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis
MGCLF MGC Pharmaceuticals Limited 2021-12-01 Phase 3 NCT04802382 Clinical Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19
NEPH Nephros, Inc. 2021-12-01 Phase 3 NCT04459338 A Dose-response Study Examining the Contribution of GLP-1 Receptor Signaling to Glucagon-stimulated Insulin Secretion
NKTR Nektar Therapeutics 2021-12-01 Phase 3 NCT03729245 A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)
OPTN OptiNose, Inc. 2021-12-01 Phase 3 NCT03781804 Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Sinusitis With or Without the Presence of Nasal Polyps
OPTN OptiNose, Inc. 2021-12-01 Phase 3 NCT03747458 OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps
SAGE Sage Therapeutics, Inc. 2021-12-01 Phase 3 NCT04476030 A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder
SLS SELLAS Life Sciences Group, Inc. 2021-12-01 Phase 3 NCT04229979 GPS Compared With BAT in AML CR2/CR2p
SPPI Spectrum Pharmaceuticals, Inc. 2021-12-01 Phase 3 NCT01478542 OPTIMAL>60 / DR. CHOP, Improvement of Therapy of Elderly Patients With CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine
SRRA Sierra Oncology, Inc. 2021-12-01 Phase 3 NCT04173494 A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Patients (MOMENTUM)
TARS Tarsus Pharmaceuticals, Inc. 2021-12-01 Phase 3 NCT04784091 Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis